80 results on '"Ownership legislation & jurisprudence"'
Search Results
2. Protecting products versus platforms.
3. Biotechnology patents under fire.
4. Myriad stands alone.
5. A patent perspective on US stem cell research.
6. Intellectual property rights in publicly funded biobanks: much ado about nothing?
7. Unsettled expectations: how recent patent decisions affect biotech.
8. Faculty and employee ownership of inventions in Australia.
9. DNA patents and diagnostics: not a pretty picture.
10. Empirical analysis of major stem cell patent cases: the role of universities.
11. Parts, property and sharing.
12. The obviousness rejection as a barrier to biotech patent prosecution.
13. Genentech's Cabilly victory.
14. A nail in the coffin for DNA sequence patents?
15. Cabilly patent finale.
16. Patent protection and access to genetic resources.
17. India's IP snub.
18. Four rebuffs for Cabilly.
19. Recent Supreme Court decisions and licensing power.
20. Patentability issues surrounding antivirals.
21. Proposed changes to patent code loom over biotech industry.
22. Patenting the parts.
23. Patents and translational research in genomics.
24. Planning your taxes in UK.
25. Time waits for no man: deciding when to file a patent application in Europe.
26. Shortened life spans of biotech pioneer patents in Japan: a lesson from the DNA chip.
27. DNA patenting: the end of an era?
28. Burning bridges.
29. Japan's novelty grace period solves the dilemma of 'publish and perish'.
30. Evidence and anecdotes: an analysis of human gene patenting controversies.
31. Emerging patent issues in genomic diagnostics.
32. The patentability of human embryonic stem cells in Europe.
33. Patenting pathways.
34. A license to print money?
35. The paths around stem cell intellectual property.
36. Navigating the future(s) of biotech intellectual property.
37. The importance of getting inventorship right.
38. Determining the meaning of claim terms.
39. Innovation and intellectual property rights in systems biology.
40. Patent pools and standard setting in diagnostic genetics.
41. Whose tissue is it anyway?
42. The zinc finger nuclease monopoly.
43. EPO neem patent revocation revives biopiracy debate.
44. US court case to define EST patentability.
45. Erythropoietin in the UK: a setback for gene patents?
46. China steps towards international M&A.
47. Stock options could no longer be the carrot.
48. The coming US patent opposition.
49. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
50. Kenyan dispute illuminates bioprospecting difficulties.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.